By Cristal Cody
Chicago, May 12 – Fresenius Medical US Finance III Inc. priced a $1.5 billion two-part offering in the Wednesday session, a market source reported.
The company sold $850 million of 1.875% notes due Dec. 1, 2026 at a Treasuries plus 110 basis points spread, low to talk in the Treasuries plus 125 bps area.
The longer-dated tranche of $650 million of 3% notes due Dec. 1, 2031 priced with a spread of 140 bps over Treasuries, again low to talk in the Treasuries plus 155 bps area.
Citigroup, Goldman Sachs, JPMorgan and Wells Fargo Securities worked as bookrunners.
The issuer is a kidney dialysis company based in Bad Homburg, Germany.
| Issuer: | Fresenius Medical US Finance III Inc.
|
| Issue: | Notes
|
| Amount: | $1.5 billion
|
| Bookrunners: | Citigroup, Goldman Sachs, JPMorgan and Wells Fargo Securities
|
| Trade date: | May 12
|
|
|
| 2026 notes
|
| Amount: | $850 million
|
| Maturity: | Dec. 1, 2026
|
| Coupon: | 1.875%
|
| Spread: | Treasuries plus 110 bps
|
| Price talk: | Treasuries plus 125 bps area
|
|
|
| 2031 notes
|
| Amount: | $650 million
|
| Maturity: | Dec. 1, 2031
|
| Coupon: | 3%
|
| Spread: | Treasuries plus 140 bps
|
| Price talk: | Treasuries plus 155 bps area
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
